Listas de seguimiento Ideas ProPicks IA Filtro Explorador de datos Gráficos Trabajo guardado

Halozyme Therapeutics, Inc.

DB:RV7

Estados Unidos / Salud / Biotecnología

Visión general

Finanzas históricas a 5 años

Precio

58.84 EUR


Key Metrics	Latest
Total Revenue	1.015 B
Adjusted EBITDA	627.1 M
EBITDA Margin	61.8%
Net Profit Margin	42.9%
Total Assets	2.063 B
Total Debt	1.537 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	267.59	443.31	660.12	829.25	1,015.32	1,015.32	829.25	1,015.32
% Growth		0.66	0.49	0.26	0.22			0.22

Adjusted EBITDA	145.84	277.30	336.07	416.93	627.09	627.09	416.93	627.09
% Margin	0.55	0.63	0.51	0.50	0.62	0.62	0.50	0.62

Adjusted EBIT	144.26	275.90	289.43	340.07	551.48	551.48	340.07	551.48
% Margin	0.54	0.62	0.44	0.41	0.54	0.54	0.41	0.54

Adjusted Net Income	129.09	419.89	222.44	269.00	436.01	436.01	269.00	436.01
% Margin	0.48	0.95	0.34	0.32	0.43	0.43	0.32	0.43

Adjusted Basic EPS	0.95	2.99	1.63	2.04	3.44	3.44	2.04	3.44

Cálculos de apoyo

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	268	443	660	829	1,015	1,015	829	1,015
% Growth	NA	65.7%	48.9%	25.6%	22.4%			22.4%

Cost of Revenue	(78)	(117)	(206)	(269)	(238)	(238)	(269)	(238)
Gross Profit	190	326	454	561	777	777	561	777
% Revenue	71.0%	73.6%	68.8%	67.6%	76.5%	76.5%	67.6%	76.5%

Research and Development	(34)	(36)	(67)	(76)	(79)	(79)	(76)	(79)
Selling and Marketing	0	0	0	0	0	0	0	0
General and Admin	(46)	(50)	(122)	(149)	(154)	(154)	(149)	(154)
Other Inc / (Exp)	34	12	(4)	22	19	19	22	19
Total Operating Exp	(46)	(74)	(192)	(203)	(214)	(214)	(203)	(214)

Operating Income	144	253	262	357	562	562	357	562
% Revenue	53.9%	57.0%	39.7%	43.1%	55.4%	55.4%	43.1%	55.4%

Interest Expense	(15)	(4)	(13)	(9)	(5)	(5)	(9)	(5)
Pre-tax Income	129	249	249	348	557	557	348	557
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(0)	154	(47)	(67)	(113)	(113)	(67)	(113)
Net Income to Company	129	403	202	282	444	444	282	444
% Margin	48.2%	90.8%	30.6%	34.0%	43.7%	43.7%	34.0%	43.7%

Minority Interest in Earnings	0	0	0	0	0	0	0	0
Net Income to Stockholders	129	403	202	282	444	444	282	444

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	129	403	202	282	444	444	282	444
% Margin	48.2%	90.8%	30.6%	34.0%	43.7%	43.7%	34.0%	43.7%

As Reported
Basic EPS (Continuing Ops)	0.95	2.86	1.48	2.13	3.50	3.50	2.13	3.50
Diluted EPS (Continuing Ops)	0.91	2.74	1.44	2.10	3.43	3.43	2.10	3.43

WA Basic Shares Out.	136.21	140.65	136.84	131.93	126.83	126.83	131.93	126.83
WA Diluted Shares Out.	141.46	146.80	140.61	134.20	129.42	129.42	134.20	129.42

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	129	249	249	348	557	557	348	557
Addback: Net Interest Expense	15	4	13	9	5	5	9	5
Addback: Other Non Operating Expenses, Total	0	0	0	0	0	0	0	0
Addback: Depreciation & Amortization	2	1	47	77	76	76	77	76
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	22	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	2	3	(6)	(11)	(11)	(6)	(11)
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	3	0	0	3	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	21	3	(13)	0	0	(13)	0
Adjusted EBITDA	146	277	336	417	627	627	417	627
% Margin	54.5%	62.6%	50.9%	50.3%	61.8%	61.8%	50.3%	61.8%

Adjusted EBIT	144	276	289	340	551	551	340	551
% Margin	53.9%	62.2%	43.8%	41.0%	54.3%	54.3%	41.0%	54.3%

Adjusted Net Income Reconciliation
Net Income to Company	129	403	202	282	444	444	282	444
Addback: Unusual Items	0	23	27	(17)	(11)	(11)	(17)	(11)
Less: Tax Benefit of Unusual Items (26%)	0	(6)	(7)	4	3	3	4	3
Adjusted Net Income	129	420	222	269	436	436	269	436
% Margin	48.2%	94.7%	33.7%	32.4%	42.9%	42.9%	32.4%	42.9%

Error de carga

Halozyme Therapeutics, Inc.

DB:RV7

Estados Unidos / Salud / Biotecnología

Finanzas históricas a 5 años